Source Name	Characteristics[sample_name]	Characteristics[organism]	Characteristics[taxonomy_id]	Characteristics[isolate]	Characteristics[biomaterial_provider]	Characteristics[collection_date]	Characteristics[geo_loc_name]	Characteristics[age]	Characteristics[disease]	Characteristics[sex]	Characteristics[tissue]	Comment[BioSample]	Comment[sample_title]	Comment[description]	Protocol REF	Protocol REF	Protocol REF	Extract Name	Material Type	Comment[LIBRARY_LAYOUT]	Comment[LIBRARY_SELECTION]	Comment[LIBRARY_SOURCE]	Comment[LIBRARY_STRATEGY]	Comment[INSTRUMENT_MODEL]	Protocol REF	Assay Name	Comment[SRA_EXPERIMENT]	Comment[SRA_RUN]	Technology Type	Array Data File	Protocol REF	Derived Array Data Matrix File	Factor Value[genetic_modification]
Sample1001	Sample1001	Homo sapiens	9606	not collected	Cellular Technology Limited	missing: control sample	missing: control sample	not collected	healthy_mixture_17	not collected	Peripheral Blood Mononuclear Cells	SAMD00853614	Sample_icRNA_resting_Ctrl_gRNA1	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) for 72 hours. Cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. 400 uM of CRISPR RNAs (crRNAs) and trans-activating CRISPR RNAs (tracrRNAs) (Integrated DNA Technologies) were mixed at a 1:1 vol/vol ratio and heated at 95C for 5 min. Following an incubation period of 15 minutes at room temperature, 30_ug of Cas9 protein (Takara, #632641) was added to 2.7 uL of 200 uM gRNA complex, and then incubated for over 15 min at room temperature before use. Pooled RNPs with two different gRNAs were also used in this study to maximize knockout efficiency of the target protein. In this case, half the amount of gRNA complex and Cas9 protein were used for preparing each RNP complex and then mixed at a 1:1 ratio. For electroporation, pre-activated CD4-positive T cells were resuspended in P2 primary nucleofection buffer at 2x10E6 cells/20 uL and mixed with RNPs in a 16-well cuvette plate. The cell-containing mixture was pulsed with the EH-100 program and electroporated cells were cultured at 1-2x10E6 cells/mL in complete medium supplemented with 500 IU/mL IL-2 for 4-6 days.	P-GEAD-3442	P-GEAD-3443	P-GEAD-3444	Sample1001	total RNA	PAIRED	cDNA_oligo_dT	TRANSCRIPTOMIC	RNA_SEQ	Illumina NovaSeq 6000	P-GEAD-3445	RNA_Ctrl1_D1_resting	DRX605279	DRR624939	sequencing assay	DRR624939	P-GEAD-3446	DRR624939_RNA_NTC_gRNA1_D1_resting_Tconv_gene_counts.txt	Non Targeting Control
Sample1001	Sample1001	Homo sapiens	9606	not collected	Cellular Technology Limited	missing: control sample	missing: control sample	not collected	healthy_mixture_17	not collected	Peripheral Blood Mononuclear Cells	SAMD00853614	Sample_icRNA_resting_Ctrl_gRNA1	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) for 72 hours. Cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. 400 uM of CRISPR RNAs (crRNAs) and trans-activating CRISPR RNAs (tracrRNAs) (Integrated DNA Technologies) were mixed at a 1:1 vol/vol ratio and heated at 95C for 5 min. Following an incubation period of 15 minutes at room temperature, 30_ug of Cas9 protein (Takara, #632641) was added to 2.7 uL of 200 uM gRNA complex, and then incubated for over 15 min at room temperature before use. Pooled RNPs with two different gRNAs were also used in this study to maximize knockout efficiency of the target protein. In this case, half the amount of gRNA complex and Cas9 protein were used for preparing each RNP complex and then mixed at a 1:1 ratio. For electroporation, pre-activated CD4-positive T cells were resuspended in P2 primary nucleofection buffer at 2x10E6 cells/20 uL and mixed with RNPs in a 16-well cuvette plate. The cell-containing mixture was pulsed with the EH-100 program and electroporated cells were cultured at 1-2x10E6 cells/mL in complete medium supplemented with 500 IU/mL IL-2 for 4-6 days.	P-GEAD-3442	P-GEAD-3443	P-GEAD-3444	Sample1001	total RNA	PAIRED	cDNA_oligo_dT	TRANSCRIPTOMIC	RNA_SEQ	Illumina NovaSeq 6000	P-GEAD-3445	RNA_Ctrl1_D2_resting	DRX605279	DRR624940	sequencing assay	DRR624940	P-GEAD-3446	DRR624940_RNA_NTC_gRNA1_D2_resting_Tconv_gene_counts.txt	Non Targeting Control
Sample1001	Sample1001	Homo sapiens	9606	not collected	Cellular Technology Limited	missing: control sample	missing: control sample	not collected	healthy_mixture_17	not collected	Peripheral Blood Mononuclear Cells	SAMD00853614	Sample_icRNA_resting_Ctrl_gRNA1	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) for 72 hours. Cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. 400 uM of CRISPR RNAs (crRNAs) and trans-activating CRISPR RNAs (tracrRNAs) (Integrated DNA Technologies) were mixed at a 1:1 vol/vol ratio and heated at 95C for 5 min. Following an incubation period of 15 minutes at room temperature, 30_ug of Cas9 protein (Takara, #632641) was added to 2.7 uL of 200 uM gRNA complex, and then incubated for over 15 min at room temperature before use. Pooled RNPs with two different gRNAs were also used in this study to maximize knockout efficiency of the target protein. In this case, half the amount of gRNA complex and Cas9 protein were used for preparing each RNP complex and then mixed at a 1:1 ratio. For electroporation, pre-activated CD4-positive T cells were resuspended in P2 primary nucleofection buffer at 2x10E6 cells/20 uL and mixed with RNPs in a 16-well cuvette plate. The cell-containing mixture was pulsed with the EH-100 program and electroporated cells were cultured at 1-2x10E6 cells/mL in complete medium supplemented with 500 IU/mL IL-2 for 4-6 days.	P-GEAD-3442	P-GEAD-3443	P-GEAD-3444	Sample1001	total RNA	PAIRED	cDNA_oligo_dT	TRANSCRIPTOMIC	RNA_SEQ	Illumina NovaSeq 6000	P-GEAD-3445	RNA_Ctrl1_D3_resting	DRX605279	DRR624941	sequencing assay	DRR624941	P-GEAD-3446	DRR624941_RNA_NTC_gRNA1_D3_resting_Tconv_gene_counts.txt	Non Targeting Control
Sample1001	Sample1001	Homo sapiens	9606	not collected	Cellular Technology Limited	missing: control sample	missing: control sample	not collected	healthy_mixture_17	not collected	Peripheral Blood Mononuclear Cells	SAMD00853614	Sample_icRNA_resting_Ctrl_gRNA1	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) for 72 hours. Cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. 400 uM of CRISPR RNAs (crRNAs) and trans-activating CRISPR RNAs (tracrRNAs) (Integrated DNA Technologies) were mixed at a 1:1 vol/vol ratio and heated at 95C for 5 min. Following an incubation period of 15 minutes at room temperature, 30_ug of Cas9 protein (Takara, #632641) was added to 2.7 uL of 200 uM gRNA complex, and then incubated for over 15 min at room temperature before use. Pooled RNPs with two different gRNAs were also used in this study to maximize knockout efficiency of the target protein. In this case, half the amount of gRNA complex and Cas9 protein were used for preparing each RNP complex and then mixed at a 1:1 ratio. For electroporation, pre-activated CD4-positive T cells were resuspended in P2 primary nucleofection buffer at 2x10E6 cells/20 uL and mixed with RNPs in a 16-well cuvette plate. The cell-containing mixture was pulsed with the EH-100 program and electroporated cells were cultured at 1-2x10E6 cells/mL in complete medium supplemented with 500 IU/mL IL-2 for 4-6 days.	P-GEAD-3442	P-GEAD-3443	P-GEAD-3444	Sample1001	total RNA	PAIRED	cDNA_oligo_dT	TRANSCRIPTOMIC	RNA_SEQ	Illumina NovaSeq 6000	P-GEAD-3445	RNA_Ctrl1_D4_resting	DRX605279	DRR624942	sequencing assay	DRR624942	P-GEAD-3446	DRR624942_RNA_NTC_gRNA1_D4_resting_Tconv_gene_counts.txt	Non Targeting Control
Sample1002	Sample1002	Homo sapiens	9606	not collected	Cellular Technology Limited	missing: control sample	missing: control sample	not collected	healthy_mixture_18	not collected	Peripheral Blood Mononuclear Cells	SAMD00853615	Sample_icRNA_resting_Ctrl_gRNA2	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) for 72 hours. Cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. 400 uM of CRISPR RNAs (crRNAs) and trans-activating CRISPR RNAs (tracrRNAs) (Integrated DNA Technologies) were mixed at a 1:1 vol/vol ratio and heated at 95C for 5 min. Following an incubation period of 15 minutes at room temperature, 30_ug of Cas9 protein (Takara, #632641) was added to 2.7 uL of 200 uM gRNA complex, and then incubated for over 15 min at room temperature before use. Pooled RNPs with two different gRNAs were also used in this study to maximize knockout efficiency of the target protein. In this case, half the amount of gRNA complex and Cas9 protein were used for preparing each RNP complex and then mixed at a 1:1 ratio. For electroporation, pre-activated CD4-positive T cells were resuspended in P2 primary nucleofection buffer at 2x10E6 cells/20 uL and mixed with RNPs in a 16-well cuvette plate. The cell-containing mixture was pulsed with the EH-100 program and electroporated cells were cultured at 1-2x10E6 cells/mL in complete medium supplemented with 500 IU/mL IL-2 for 4-6 days.	P-GEAD-3442	P-GEAD-3443	P-GEAD-3444	Sample1002	total RNA	PAIRED	cDNA_oligo_dT	TRANSCRIPTOMIC	RNA_SEQ	Illumina NovaSeq 6000	P-GEAD-3445	RNA_Ctrl2_D1_resting	DRX605280	DRR624943	sequencing assay	DRR624943	P-GEAD-3446	DRR624943_RNA_NTC_gRNA2_D1_resting_Tconv_gene_counts.txt	Non Targeting Control
Sample1002	Sample1002	Homo sapiens	9606	not collected	Cellular Technology Limited	missing: control sample	missing: control sample	not collected	healthy_mixture_18	not collected	Peripheral Blood Mononuclear Cells	SAMD00853615	Sample_icRNA_resting_Ctrl_gRNA2	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) for 72 hours. Cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. 400 uM of CRISPR RNAs (crRNAs) and trans-activating CRISPR RNAs (tracrRNAs) (Integrated DNA Technologies) were mixed at a 1:1 vol/vol ratio and heated at 95C for 5 min. Following an incubation period of 15 minutes at room temperature, 30_ug of Cas9 protein (Takara, #632641) was added to 2.7 uL of 200 uM gRNA complex, and then incubated for over 15 min at room temperature before use. Pooled RNPs with two different gRNAs were also used in this study to maximize knockout efficiency of the target protein. In this case, half the amount of gRNA complex and Cas9 protein were used for preparing each RNP complex and then mixed at a 1:1 ratio. For electroporation, pre-activated CD4-positive T cells were resuspended in P2 primary nucleofection buffer at 2x10E6 cells/20 uL and mixed with RNPs in a 16-well cuvette plate. The cell-containing mixture was pulsed with the EH-100 program and electroporated cells were cultured at 1-2x10E6 cells/mL in complete medium supplemented with 500 IU/mL IL-2 for 4-6 days.	P-GEAD-3442	P-GEAD-3443	P-GEAD-3444	Sample1002	total RNA	PAIRED	cDNA_oligo_dT	TRANSCRIPTOMIC	RNA_SEQ	Illumina NovaSeq 6000	P-GEAD-3445	RNA_Ctrl2_D2_resting	DRX605280	DRR624944	sequencing assay	DRR624944	P-GEAD-3446	DRR624944_RNA_NTC_gRNA2_D2_resting_Tconv_gene_counts.txt	Non Targeting Control
Sample1002	Sample1002	Homo sapiens	9606	not collected	Cellular Technology Limited	missing: control sample	missing: control sample	not collected	healthy_mixture_18	not collected	Peripheral Blood Mononuclear Cells	SAMD00853615	Sample_icRNA_resting_Ctrl_gRNA2	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) for 72 hours. Cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. 400 uM of CRISPR RNAs (crRNAs) and trans-activating CRISPR RNAs (tracrRNAs) (Integrated DNA Technologies) were mixed at a 1:1 vol/vol ratio and heated at 95C for 5 min. Following an incubation period of 15 minutes at room temperature, 30_ug of Cas9 protein (Takara, #632641) was added to 2.7 uL of 200 uM gRNA complex, and then incubated for over 15 min at room temperature before use. Pooled RNPs with two different gRNAs were also used in this study to maximize knockout efficiency of the target protein. In this case, half the amount of gRNA complex and Cas9 protein were used for preparing each RNP complex and then mixed at a 1:1 ratio. For electroporation, pre-activated CD4-positive T cells were resuspended in P2 primary nucleofection buffer at 2x10E6 cells/20 uL and mixed with RNPs in a 16-well cuvette plate. The cell-containing mixture was pulsed with the EH-100 program and electroporated cells were cultured at 1-2x10E6 cells/mL in complete medium supplemented with 500 IU/mL IL-2 for 4-6 days.	P-GEAD-3442	P-GEAD-3443	P-GEAD-3444	Sample1002	total RNA	PAIRED	cDNA_oligo_dT	TRANSCRIPTOMIC	RNA_SEQ	Illumina NovaSeq 6000	P-GEAD-3445	RNA_Ctrl2_D3_resting	DRX605280	DRR624945	sequencing assay	DRR624945	P-GEAD-3446	DRR624945_RNA_NTC_gRNA2_D3_resting_Tconv_gene_counts.txt	Non Targeting Control
Sample1002	Sample1002	Homo sapiens	9606	not collected	Cellular Technology Limited	missing: control sample	missing: control sample	not collected	healthy_mixture_18	not collected	Peripheral Blood Mononuclear Cells	SAMD00853615	Sample_icRNA_resting_Ctrl_gRNA2	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) for 72 hours. Cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. 400 uM of CRISPR RNAs (crRNAs) and trans-activating CRISPR RNAs (tracrRNAs) (Integrated DNA Technologies) were mixed at a 1:1 vol/vol ratio and heated at 95C for 5 min. Following an incubation period of 15 minutes at room temperature, 30_ug of Cas9 protein (Takara, #632641) was added to 2.7 uL of 200 uM gRNA complex, and then incubated for over 15 min at room temperature before use. Pooled RNPs with two different gRNAs were also used in this study to maximize knockout efficiency of the target protein. In this case, half the amount of gRNA complex and Cas9 protein were used for preparing each RNP complex and then mixed at a 1:1 ratio. For electroporation, pre-activated CD4-positive T cells were resuspended in P2 primary nucleofection buffer at 2x10E6 cells/20 uL and mixed with RNPs in a 16-well cuvette plate. The cell-containing mixture was pulsed with the EH-100 program and electroporated cells were cultured at 1-2x10E6 cells/mL in complete medium supplemented with 500 IU/mL IL-2 for 4-6 days.	P-GEAD-3442	P-GEAD-3443	P-GEAD-3444	Sample1002	total RNA	PAIRED	cDNA_oligo_dT	TRANSCRIPTOMIC	RNA_SEQ	Illumina NovaSeq 6000	P-GEAD-3445	RNA_Ctrl2_D4_resting	DRX605280	DRR624946	sequencing assay	DRR624946	P-GEAD-3446	DRR624946_RNA_NTC_gRNA2_D4_resting_Tconv_gene_counts.txt	Non Targeting Control
Sample1003	Sample1003	Homo sapiens	9606	not collected	Cellular Technology Limited	missing: control sample	missing: control sample	not collected	healthy_mixture_19	not collected	Peripheral Blood Mononuclear Cells	SAMD00853616	Sample_icRNA_resting_KO_gRNA1_FOXP3	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) for 72 hours. Cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. 400 uM of CRISPR RNAs (crRNAs) and trans-activating CRISPR RNAs (tracrRNAs) (Integrated DNA Technologies) were mixed at a 1:1 vol/vol ratio and heated at 95C for 5 min. Following an incubation period of 15 minutes at room temperature, 30_ug of Cas9 protein (Takara, #632641) was added to 2.7 uL of 200 uM gRNA complex, and then incubated for over 15 min at room temperature before use. Pooled RNPs with two different gRNAs were also used in this study to maximize knockout efficiency of the target protein. In this case, half the amount of gRNA complex and Cas9 protein were used for preparing each RNP complex and then mixed at a 1:1 ratio. For electroporation, pre-activated CD4-positive T cells were resuspended in P2 primary nucleofection buffer at 2x10E6 cells/20 uL and mixed with RNPs in a 16-well cuvette plate. The cell-containing mixture was pulsed with the EH-100 program and electroporated cells were cultured at 1-2x10E6 cells/mL in complete medium supplemented with 500 IU/mL IL-2 for 4-6 days.	P-GEAD-3442	P-GEAD-3443	P-GEAD-3444	Sample1003	total RNA	PAIRED	cDNA_oligo_dT	TRANSCRIPTOMIC	RNA_SEQ	Illumina NovaSeq 6000	P-GEAD-3445	RNA_KO_gRNA1_D1_resting	DRX605281	DRR624947	sequencing assay	DRR624947	P-GEAD-3446	DRR624947_RNA_FOXP3_KO_gRNA1_D1_resting_Tconv_gene_counts.txt	RBPJ knockout
Sample1003	Sample1003	Homo sapiens	9606	not collected	Cellular Technology Limited	missing: control sample	missing: control sample	not collected	healthy_mixture_19	not collected	Peripheral Blood Mononuclear Cells	SAMD00853616	Sample_icRNA_resting_KO_gRNA1_FOXP3	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) for 72 hours. Cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. 400 uM of CRISPR RNAs (crRNAs) and trans-activating CRISPR RNAs (tracrRNAs) (Integrated DNA Technologies) were mixed at a 1:1 vol/vol ratio and heated at 95C for 5 min. Following an incubation period of 15 minutes at room temperature, 30_ug of Cas9 protein (Takara, #632641) was added to 2.7 uL of 200 uM gRNA complex, and then incubated for over 15 min at room temperature before use. Pooled RNPs with two different gRNAs were also used in this study to maximize knockout efficiency of the target protein. In this case, half the amount of gRNA complex and Cas9 protein were used for preparing each RNP complex and then mixed at a 1:1 ratio. For electroporation, pre-activated CD4-positive T cells were resuspended in P2 primary nucleofection buffer at 2x10E6 cells/20 uL and mixed with RNPs in a 16-well cuvette plate. The cell-containing mixture was pulsed with the EH-100 program and electroporated cells were cultured at 1-2x10E6 cells/mL in complete medium supplemented with 500 IU/mL IL-2 for 4-6 days.	P-GEAD-3442	P-GEAD-3443	P-GEAD-3444	Sample1003	total RNA	PAIRED	cDNA_oligo_dT	TRANSCRIPTOMIC	RNA_SEQ	Illumina NovaSeq 6000	P-GEAD-3445	RNA_KO_gRNA1_D2_resting	DRX605281	DRR624948	sequencing assay	DRR624948	P-GEAD-3446	DRR624948_RNA_FOXP3_KO_gRNA1_D2_resting_Tconv_gene_counts.txt	RBPJ knockout
Sample1003	Sample1003	Homo sapiens	9606	not collected	Cellular Technology Limited	missing: control sample	missing: control sample	not collected	healthy_mixture_19	not collected	Peripheral Blood Mononuclear Cells	SAMD00853616	Sample_icRNA_resting_KO_gRNA1_FOXP3	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) for 72 hours. Cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. 400 uM of CRISPR RNAs (crRNAs) and trans-activating CRISPR RNAs (tracrRNAs) (Integrated DNA Technologies) were mixed at a 1:1 vol/vol ratio and heated at 95C for 5 min. Following an incubation period of 15 minutes at room temperature, 30_ug of Cas9 protein (Takara, #632641) was added to 2.7 uL of 200 uM gRNA complex, and then incubated for over 15 min at room temperature before use. Pooled RNPs with two different gRNAs were also used in this study to maximize knockout efficiency of the target protein. In this case, half the amount of gRNA complex and Cas9 protein were used for preparing each RNP complex and then mixed at a 1:1 ratio. For electroporation, pre-activated CD4-positive T cells were resuspended in P2 primary nucleofection buffer at 2x10E6 cells/20 uL and mixed with RNPs in a 16-well cuvette plate. The cell-containing mixture was pulsed with the EH-100 program and electroporated cells were cultured at 1-2x10E6 cells/mL in complete medium supplemented with 500 IU/mL IL-2 for 4-6 days.	P-GEAD-3442	P-GEAD-3443	P-GEAD-3444	Sample1003	total RNA	PAIRED	cDNA_oligo_dT	TRANSCRIPTOMIC	RNA_SEQ	Illumina NovaSeq 6000	P-GEAD-3445	RNA_KO_gRNA1_D3_resting	DRX605281	DRR624949	sequencing assay	DRR624949	P-GEAD-3446	DRR624949_RNA_FOXP3_KO_gRNA1_D3_resting_Tconv_gene_counts.txt	RBPJ knockout
Sample1003	Sample1003	Homo sapiens	9606	not collected	Cellular Technology Limited	missing: control sample	missing: control sample	not collected	healthy_mixture_19	not collected	Peripheral Blood Mononuclear Cells	SAMD00853616	Sample_icRNA_resting_KO_gRNA1_FOXP3	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) for 72 hours. Cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. 400 uM of CRISPR RNAs (crRNAs) and trans-activating CRISPR RNAs (tracrRNAs) (Integrated DNA Technologies) were mixed at a 1:1 vol/vol ratio and heated at 95C for 5 min. Following an incubation period of 15 minutes at room temperature, 30_ug of Cas9 protein (Takara, #632641) was added to 2.7 uL of 200 uM gRNA complex, and then incubated for over 15 min at room temperature before use. Pooled RNPs with two different gRNAs were also used in this study to maximize knockout efficiency of the target protein. In this case, half the amount of gRNA complex and Cas9 protein were used for preparing each RNP complex and then mixed at a 1:1 ratio. For electroporation, pre-activated CD4-positive T cells were resuspended in P2 primary nucleofection buffer at 2x10E6 cells/20 uL and mixed with RNPs in a 16-well cuvette plate. The cell-containing mixture was pulsed with the EH-100 program and electroporated cells were cultured at 1-2x10E6 cells/mL in complete medium supplemented with 500 IU/mL IL-2 for 4-6 days.	P-GEAD-3442	P-GEAD-3443	P-GEAD-3444	Sample1003	total RNA	PAIRED	cDNA_oligo_dT	TRANSCRIPTOMIC	RNA_SEQ	Illumina NovaSeq 6000	P-GEAD-3445	RNA_KO_gRNA1_D4_resting	DRX605281	DRR624950	sequencing assay	DRR624950	P-GEAD-3446	DRR624950_RNA_FOXP3_KO_gRNA1_D4_resting_Tconv_gene_counts.txt	RBPJ knockout
Sample1004	Sample1004	Homo sapiens	9606	not collected	Cellular Technology Limited	missing: control sample	missing: control sample	not collected	healthy_mixture_20	not collected	Peripheral Blood Mononuclear Cells	SAMD00853617	Sample_icRNA_resting_KO_gRNA2_FOXP3	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) for 72 hours. Cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. 400 uM of CRISPR RNAs (crRNAs) and trans-activating CRISPR RNAs (tracrRNAs) (Integrated DNA Technologies) were mixed at a 1:1 vol/vol ratio and heated at 95C for 5 min. Following an incubation period of 15 minutes at room temperature, 30_ug of Cas9 protein (Takara, #632641) was added to 2.7 uL of 200 uM gRNA complex, and then incubated for over 15 min at room temperature before use. Pooled RNPs with two different gRNAs were also used in this study to maximize knockout efficiency of the target protein. In this case, half the amount of gRNA complex and Cas9 protein were used for preparing each RNP complex and then mixed at a 1:1 ratio. For electroporation, pre-activated CD4-positive T cells were resuspended in P2 primary nucleofection buffer at 2x10E6 cells/20 uL and mixed with RNPs in a 16-well cuvette plate. The cell-containing mixture was pulsed with the EH-100 program and electroporated cells were cultured at 1-2x10E6 cells/mL in complete medium supplemented with 500 IU/mL IL-2 for 4-6 days.	P-GEAD-3442	P-GEAD-3443	P-GEAD-3444	Sample1004	total RNA	PAIRED	cDNA_oligo_dT	TRANSCRIPTOMIC	RNA_SEQ	Illumina NovaSeq 6000	P-GEAD-3445	RNA_KO_gRNA2_D1_resting	DRX605282	DRR624951	sequencing assay	DRR624951	P-GEAD-3446	DRR624951_RNA_FOXP3_KO_gRNA2_D1_resting_Tconv_gene_counts.txt	RBPJ knockout
Sample1004	Sample1004	Homo sapiens	9606	not collected	Cellular Technology Limited	missing: control sample	missing: control sample	not collected	healthy_mixture_20	not collected	Peripheral Blood Mononuclear Cells	SAMD00853617	Sample_icRNA_resting_KO_gRNA2_FOXP3	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) for 72 hours. Cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. 400 uM of CRISPR RNAs (crRNAs) and trans-activating CRISPR RNAs (tracrRNAs) (Integrated DNA Technologies) were mixed at a 1:1 vol/vol ratio and heated at 95C for 5 min. Following an incubation period of 15 minutes at room temperature, 30_ug of Cas9 protein (Takara, #632641) was added to 2.7 uL of 200 uM gRNA complex, and then incubated for over 15 min at room temperature before use. Pooled RNPs with two different gRNAs were also used in this study to maximize knockout efficiency of the target protein. In this case, half the amount of gRNA complex and Cas9 protein were used for preparing each RNP complex and then mixed at a 1:1 ratio. For electroporation, pre-activated CD4-positive T cells were resuspended in P2 primary nucleofection buffer at 2x10E6 cells/20 uL and mixed with RNPs in a 16-well cuvette plate. The cell-containing mixture was pulsed with the EH-100 program and electroporated cells were cultured at 1-2x10E6 cells/mL in complete medium supplemented with 500 IU/mL IL-2 for 4-6 days.	P-GEAD-3442	P-GEAD-3443	P-GEAD-3444	Sample1004	total RNA	PAIRED	cDNA_oligo_dT	TRANSCRIPTOMIC	RNA_SEQ	Illumina NovaSeq 6000	P-GEAD-3445	RNA_KO_gRNA2_D2_resting	DRX605282	DRR624952	sequencing assay	DRR624952	P-GEAD-3446	DRR624952_RNA_FOXP3_KO_gRNA2_D2_resting_Tconv_gene_counts.txt	RBPJ knockout
Sample1004	Sample1004	Homo sapiens	9606	not collected	Cellular Technology Limited	missing: control sample	missing: control sample	not collected	healthy_mixture_20	not collected	Peripheral Blood Mononuclear Cells	SAMD00853617	Sample_icRNA_resting_KO_gRNA2_FOXP3	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) for 72 hours. Cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. 400 uM of CRISPR RNAs (crRNAs) and trans-activating CRISPR RNAs (tracrRNAs) (Integrated DNA Technologies) were mixed at a 1:1 vol/vol ratio and heated at 95C for 5 min. Following an incubation period of 15 minutes at room temperature, 30_ug of Cas9 protein (Takara, #632641) was added to 2.7 uL of 200 uM gRNA complex, and then incubated for over 15 min at room temperature before use. Pooled RNPs with two different gRNAs were also used in this study to maximize knockout efficiency of the target protein. In this case, half the amount of gRNA complex and Cas9 protein were used for preparing each RNP complex and then mixed at a 1:1 ratio. For electroporation, pre-activated CD4-positive T cells were resuspended in P2 primary nucleofection buffer at 2x10E6 cells/20 uL and mixed with RNPs in a 16-well cuvette plate. The cell-containing mixture was pulsed with the EH-100 program and electroporated cells were cultured at 1-2x10E6 cells/mL in complete medium supplemented with 500 IU/mL IL-2 for 4-6 days.	P-GEAD-3442	P-GEAD-3443	P-GEAD-3444	Sample1004	total RNA	PAIRED	cDNA_oligo_dT	TRANSCRIPTOMIC	RNA_SEQ	Illumina NovaSeq 6000	P-GEAD-3445	RNA_KO_gRNA2_D3_resting	DRX605282	DRR624953	sequencing assay	DRR624953	P-GEAD-3446	DRR624953_RNA_FOXP3_KO_gRNA2_D3_resting_Tconv_gene_counts.txt	RBPJ knockout
Sample1004	Sample1004	Homo sapiens	9606	not collected	Cellular Technology Limited	missing: control sample	missing: control sample	not collected	healthy_mixture_20	not collected	Peripheral Blood Mononuclear Cells	SAMD00853617	Sample_icRNA_resting_KO_gRNA2_FOXP3	Naive CD4 Tconv cells were sorted from PBMC (Day 0). Cells were stimulated with plate-bound anti-human CD3 (10 ug/mL; clone UCHT1) for 72 hours. Cells were collected and resuspended with freshly prepared medium including 500 IU/mL of hIL-2 (Day 3) and expanded for 6 days. 400 uM of CRISPR RNAs (crRNAs) and trans-activating CRISPR RNAs (tracrRNAs) (Integrated DNA Technologies) were mixed at a 1:1 vol/vol ratio and heated at 95C for 5 min. Following an incubation period of 15 minutes at room temperature, 30_ug of Cas9 protein (Takara, #632641) was added to 2.7 uL of 200 uM gRNA complex, and then incubated for over 15 min at room temperature before use. Pooled RNPs with two different gRNAs were also used in this study to maximize knockout efficiency of the target protein. In this case, half the amount of gRNA complex and Cas9 protein were used for preparing each RNP complex and then mixed at a 1:1 ratio. For electroporation, pre-activated CD4-positive T cells were resuspended in P2 primary nucleofection buffer at 2x10E6 cells/20 uL and mixed with RNPs in a 16-well cuvette plate. The cell-containing mixture was pulsed with the EH-100 program and electroporated cells were cultured at 1-2x10E6 cells/mL in complete medium supplemented with 500 IU/mL IL-2 for 4-6 days.	P-GEAD-3442	P-GEAD-3443	P-GEAD-3444	Sample1004	total RNA	PAIRED	cDNA_oligo_dT	TRANSCRIPTOMIC	RNA_SEQ	Illumina NovaSeq 6000	P-GEAD-3445	RNA_KO_gRNA2_D4_resting	DRX605282	DRR624954	sequencing assay	DRR624954	P-GEAD-3446	DRR624954_RNA_FOXP3_KO_gRNA2_D4_resting_Tconv_gene_counts.txt	RBPJ knockout